Complementing the Path to Chimeric Antigen Receptor (CAR)-T: Pegcetacoplan Rescue in Refractory Lupus Nephritis (KIDNEY WEEK 2026) - Oct 2, 2026 - Abstract #SA-PO0754; Pres time: Oct 24, 2026; 10:00 AM - 12:00 PM; Location: Exhibit Hall A, Convention Center; "Prior treatment included cyclophosphamide, belimumab, prednisone, voclosporin, mycophenolate mofetil, and rituximab. Pegcetacoplan's unique mechanism of action, including its titratable intensity of complement blockade, suggests it may serve as a stabilizing therapeutic or bridge in LN while patients prepare for definitive management. Further investigation is warranted to define the role of complement inhibition in LN."
Antibody-mediated Rejection • Glomerulonephritis • Immunology • Inflammatory Arthritis • Lupus • Lupus Nephritis • Nephrology • Renal Disease
|
|
Nicole Jami Kent; Jennifer L. Grigsby; Kirk W. Foster; Jennifer Medlin; Prasanth Ravipati
|